scholarly journals Impact of Heart Transplantation on Cheyne-Stokes Respiration in a Child

2016 ◽  
Vol 2016 ◽  
pp. 1-3 ◽  
Author(s):  
Suhail Al-Saleh ◽  
Paul F. Kantor ◽  
Indra Narang
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Dilated Cardiomyopathy ◽  
Heart Transplant ◽  
Cardiac Transplantation ◽  
Sleep Disordered Breathing ◽  
Pediatric Population ◽  
Severe Heart Failure ◽  
Advanced Heart Failure ◽  
Caucasian Male

Sleep disordered breathing is well described in adults with heart failure but not in pediatric population. We describe a 13-year-old Caucasian male with severe heart failure related to dilated cardiomyopathy who demonstrated polysomnographic features of Cheyne-Stokes respiration, which completely resolved following cardiac transplantation. Cheyne-Stokes respiration in children with advanced heart failure and its resolution after heart transplant can be observed similar to adults.

scholarly journals Influence of Gender in Advanced Heart Failure Therapies and Outcome Following Transplantation

2021 ◽  
Vol 8 ◽  
Author(s):  
María Dolores García-Cosío ◽  
Francisco González-Vilchez ◽  
Raquel López-Vilella ◽  
Eduardo Barge-Caballero ◽  
Manuel Gómez Bueno ◽  
...  
Keyword(s):  
Heart Failure ◽  
Sex Differences ◽  
Heart Transplantation ◽  
Heart Transplant ◽  
Advanced Heart Failure ◽  
Waiting List ◽  
Ventricular Assist Devices ◽  
Long Term Results ◽  
Current Evidence ◽  
Men And Women

Biological differences between males and females change the course of different diseases and affect therapeutic measures' responses. Heart failure is not an exception to these differences. Women account for a minority of patients on the waiting list for heart transplantation or other advanced heart failure therapies. The reason for this under-representation is unknown. Men have a worse cardiovascular risk profile and suffer more often from ischemic heart disease. Conversely, transplanted women are younger and more frequently have non-ischemic cardiac disorders. Women's poorer survival on the waiting list for heart transplantation has been previously described, but this trend has been corrected in recent years. The use of ventricular assist devices in women is progressively increasing, with comparable results than in men. The indication rate for a heart transplant in women (number of women on the waiting list for millions of habitants) has remained unchanged over the past 25 years. Long-term results of heart transplants are equal for both men and women. We have analyzed the data of a national registry of heart transplant patients to look for possible future directions for a more in-depth study of sex differences in this area. We have analyzed 1-year outcomes of heart transplant recipients. We found similar results in men and women and no sex-related interactions with any of the factors related to survival or differences in death causes between men and women. We should keep trying to approach sex differences in prospective studies to confirm if they deserve a different approach, which is not supported by current evidence.

Anesthesia for Cardiac Transplantation

2019 ◽  
pp. 244-257
Author(s):  
Stefan Lombaard ◽  
Heather Reed ◽  
Samantha Arzillo
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Heart Transplant ◽  
Cardiac Transplantation ◽  
Treatment Options ◽  
Definitive Therapy ◽  
Patients With Heart Failure ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Induction Agents

Heart transplantation is indicated when other treatment options for patients with heart failure are no longer effective or when a heart transplant would improve survival. There are currently a variety of treatment options for these patients; the options range from medical therapy to full mechanical support. Heart transplantation remains the definitive therapy for end-stage heart failure. This discussion focuses on the management of a patient who presents for a heart transplant as well as some of the challenging clinical issues that may present during this period. Anesthetic induction agents may depress cardiovascular function and result in cardiovascular collapse. Drugs should be chosen that have limited hemodynamic effects.

scholarly journals Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies

2021 ◽  
Vol 3 (2) ◽  
pp. 294-301
Author(s):  
Bhavadharini Ramu ◽  
Maria Masotti ◽  
Ryan J. Tedford ◽  
Rebecca J. Cogswell
Keyword(s):  
Heart Failure ◽  
Heart Transplantation ◽  
Advanced Heart Failure

Baseline and 6-month B-type natriuretic peptide changes are independent predictors of events in patients with advanced heart failure awaiting cardiac transplantation

2009 ◽  
Vol 10 (9) ◽  
pp. 671-676 ◽  
Author(s):  
Carlo Campana ◽  
Michele Pasotti ◽  
Catherine Klersy ◽  
Giuseppe Alessandrino ◽  
Riccardo Albertini ◽  
...  
Keyword(s):  
Heart Failure ◽  
Natriuretic Peptide ◽  
Cardiac Transplantation ◽  
Advanced Heart Failure

Abstract 5853: Continuous Flow Left Ventricular Assist Device in Women with Advanced Heart Failure: Results After One Year of Support

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Salpy V Pamboukian ◽  
Roberta C Bogaev ◽  
Stuart D Russell ◽  
Andrew J Boyle ◽  
Nader Moazami ◽  
...  
Keyword(s):  
Heart Failure ◽  
Continuous Flow ◽  
Cardiac Transplantation ◽  
Causes Of Death ◽  
Left Ventricular ◽  
Advanced Heart Failure ◽  
Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
One Year

Small continuous flow left ventricular assist devices (LVAD) are providing new options for women in advanced heart failure who due to body size limitations were historically excluded from use of large first generation pulsatile devices. We report the experience of women one year after implantation with the new, HeartMate II continuous flow LVAD for bridge to transplantation. Patients (n=279), 24% female (F), 76% male (M) in NYHA Class IV heart failure, LV ejection fraction 16±7% (F), 16±6% (M), mostly inotrope dependent and about half on intraaortic balloon pump support (50% F, 43% M), who had been enrolled in the HM II clinical trial for at least 1 year as a bridge to cardiac transplantation at 33 centers were analyzed. Outcomes and causes of death in the first year of support between F and M recipients were determined. The percentage of patients who had undergone transplantation, recovery of the heart with device removal, or continued on HM II support after one year were the same (80%) between M and F. However, the percentage of patients who had received a heart transplant was significantly less for F (38%) than M (53%) (p<0.05). Median duration of support for F was 226 days (range 8–1004) vs. 143 days (range 0–1057) for M. Mortality on device support was 20% for F and 18% M. There were no statistically significant differences in leading causes of death: sepsis (1.5% F vs 4.2% M), ischemic stroke (3.1% F vs 1.9% M), hemorrhagic stroke (3.1% F vs 1.4% M), and right heart failure (3.1% F vs 1.9% M). Of 82 patients continuing on support at 1 year, 26 (32%) were F with median BSA of 1.65 vs 2.14 m 2 for M. Kaplan Meier survival at one year was similar for females (74%) and males (76%). The smaller, more durable HM II rotary LVAD may be especially advantageous to women with advanced HF as a bridge to cardiac transplantation, because of significantly smaller BSA and need for extended duration of mechanical support due to longer wait times for suitable organ donors. Outcomes at one-year

scholarly journals Growth hormone resistance in severe heart failure resolves after cardiac transplantation

2009 ◽  
Vol 11 (5) ◽  
pp. 525-528 ◽  
Author(s):  
Lars H. Lund ◽  
Pamela Freda ◽  
Jill J. Williams ◽  
John J. LaManca ◽  
Thierry H. LeJemtel ◽  
...  
Keyword(s):  
Heart Failure ◽  
Growth Hormone ◽  
Cardiac Transplantation ◽  
Severe Heart Failure ◽  
Hormone Resistance ◽  
Growth Hormone Resistance
Sign in / Sign up

Export Citation Format

Share Document